Skip to main content
. 2016 Oct 24;36(17):2345–2354. doi: 10.1038/onc.2016.391

Figure 4.

Figure 4

Metformin-induced let-7 upregulation and H19 repression activates SAHH, leading to DNMT3B-mediated hypermethylation of H19 promoter in breast cancer MCF-7 cells. (a, b) MCF-7 cells were treated with metformin or AICAR for the indicated time frame, followed by measurement of RNA levels of let-7 (a) and H19 (b) 12 and 48 h later. (c) MCF-7 cells were treated with or without metformin, followed by evaluation of in vivo SAHH activity. (d) MCF-7 cells were transfected with siCon or siDnmt3b. Twenty-four hours later, cells were treated with or without metformin, followed by QMSP analysis of H19 promoter 24 h later. (e) reverse transcriptase–quantitative PCR analysis to confirm Dnmt3b knockdown 48 h following siRNA transfection in MCF-7 cells. Numbers are mean±s.d. (n=3). **P<0.01; *P<0.05; NS, no statistical difference.